Evidence map›Paper›PMID 42774679›Full record

ArticleHeart rhythm O22026

Drug-drug interactions of NOACs with comedication: Prevalence and implications for adverse events in patients with atrial fibrillation.

Elisa Hennings, Stefanie Aeschbacher, Pia Neuschwander, Michael Coslovsky, Ioanna Istampoulouoglou, Anne Leuppi-Taegtmeyer, Rebecca E Paladini, Lukas Strobel, Tobias Reichlin, Nicolas Rodondi and 16 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02105844 (Swiss Atrial Fibrillation Cohort Study - SWISS AF), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02105844 active not recruitingnot on this map

Swiss Atrial Fibrillation Cohort Study - SWISS AF

TypeobservationalSponsorUniversity Hospital, Basel, SwitzerlandRan2014 to 2030Enrolled2,415ConditionsAtrial Fibrillation
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Elisa HenningsCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Stefanie AeschbacherCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Pia NeuschwanderDepartment of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Michael CoslovskyDepartment of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Ioanna IstampoulouoglouDepartment of Clinical Pharmacology & Toxicology, University Hospital Basel, University of Basel, Basel, Switzerland.
Anne Leuppi-TaegtmeyerDepartment of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Rebecca E PaladiniCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Lukas StrobelCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Tobias ReichlinDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Nicolas RodondiDepartment of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Jürg H BeerDepartment of Internal Medicine, Cantonal Hospital Baden, Baden, Switzerland.
Giulio ConteCardiology Division, Cardiocentro Ticino Institute, Regional Hospital of Lugano, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
Angelo AuricchioCardiology Division, Cardiocentro Ticino Institute, Regional Hospital of Lugano, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
Giorgio MoschovitisCardiology Division, Cardiocentro Ticino Institute, Regional Hospital of Lugano, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
Marcello Di ValentinoCardiology Division, Cardiocentro Ticino Institute, Regional Hospital of Lugano, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Luise AdamInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Maria Luisa De PernaCardiology Division, Cardiocentro Ticino Institute, Regional Hospital of Lugano, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
Leo H BonatiDepartment of Neurology and Stroke Center, University Hospital Basel, University of Basel, Basel, Switzerland.
Felix MahfoudCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Philipp KrisaiCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Christine S ZuernCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
David ConenPopulation Health Research Institute, McMaster University, Hamilton, Canada.
Christian SticherlingCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Stefan OsswaldCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Michael KühneCardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Swiss-AF Investigators17

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The clinical relevance of drug-drug interactions associated with non‒vitamin K-antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) remains poorly understood. Objective: We evaluated the prevalence of pharmacokinetic and pharmacodynamic drug-drug interactions and their association with adverse clinical outcomes in patients with AF receiving NOACs. Methods: We analyzed patients from the prospective, multicenter Swiss-AF cohort study. We used frailty survival models to investigate the association of the different potential interactions with the respective clinical adverse outcomes (major bleeding, clinically relevant non-major bleeding, any bleeding, ischemic stroke or systemic embolism). Results: Our analysis comprised 1732 patients with AF (mean age 73 ± 8 years, 501 [29%] women) with a median follow-up period of 6 years. For 683 of these patients (39%), we recorded ≥1 potential drug-drug interaction. In the multivariable adjusted model, the hazard ratio of drug-drug interaction was 1.21 (95% confidence interval [CI] 0.84-1.75, Conclusion: In a large real-world cohort of patients with AF, the prevalence of potential interactions of long-term comedication with NOACs was high. We found no strong evidence of an association between these interactions and an increased risk of bleeding or the composite outcome ischemic stroke or systemic embolism. Registration: Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT02105844. ClinicalTrialsgov Identifier: NCT02105844.

Indexed as

Atrial fibrillationBleedingDrug-drug interactionNOACStroke

Identifiers

PMID42774679
PMCPMC13594476

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.